首页>The Journal of Antimicrobial Chemotherapy>Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)
作者单位:Pathology Service, Hospital San Pedro, Logro, Spain[1]Infectious Diseases Department, Center for Biomedical Research of La Rioja (CIBIR), Logro, Spain[2]Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logro, Spain[3]